Event Panel Schedule


TBA
Clin­i­cal In­sights of New Rapid­ly Act­ing, NM­DA-based An­tide­pres­sants
Funkyserver
NeuroRx
Robert Eric Besthof , CMO / NeuroRx
Mr. Robert Besthof serves as Chief Commercial Officer at NeuroRx. He is a global biopharmaceutical executive with a 25+year career covering global pipeline & country operational marketing & sales roles. He has managed numerous specialty…

TBA
NK cell ex­pan­sion and pro­lif­er­a­tion with PM21 par­ti­cles: ad­junc­tive ther­a­py for he­ma­topoi­et­ic stem cell tran­s­plan­ta­tion and po­ten­tial treat­ment for both liquid and solid tu­mors
C0cf89ac7acb92a11e9315911029932a_3181c93db9cc9bdb36b342d21147fcf5_120_120
Kiadis Pharma N.V.
Arthur Lahr , CEO / Kiadis Pharma N.V.
Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Before that he…

TBA
Three clin­i­cal-stage cell ther­a­py pro­grams in dry age-re­lat­ed mac­u­lar de­gen­er­a­tion, spi­nal cord in­jury, and on­col­o­gy
D6e9e3e9adbcb505f8c71a5f023008a2_3742d14743ac09839fb1271fcc03a121_120_120
Lineage Cell Therapeutics Inc.
Brian Culley , CEO/Interim CFO / Lineage Cell Therapeutics Inc.
Mr. Culley joined Lineage Cell Therapeutics as CEO in September 2018. Prior to joining Lineage Cell Therapeutics, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he…

TBA
SCLC: Re­cent ap­pro­vals in first and third line could be joined with Lur­binecte­din in 2nd line
095a5fd4a4e314256ed98b79ebe9a80d_60e17f4533de76edf1f8c6480ea4cfdd_120_120
PharmaMar SA
Pascal Besman , Chief Operating Officer (PharmaMar U.S.) / PharmaMar SA
Prior to joining JMP, Pascal was a partner and institutional salesperson at Maxim and also ThinkEquity for three years. He previously served as a senior vice president at UBS and has held equity sales positions at Bear Stearns, Lehman Brothers and…

TBA
On­co­lyt­ic ade­n­ovirus armed w im­mune sti­m­u­lat­ing trans­gene tar­get­ing bas­ket of I-O in­di­ca­tions
3b15ad5db4b8b6b92334e8458316f1d5_f30a348a9ea1fa8873e1662bd52fb961_120_120
Targovax
Torbjørn Furuseth , Chief Financial Officer / Targovax
An experienced executive with a broad background within life science. He joins from the clinical stage immune-oncology company Lytix Biopharma, where he has served as CFO and conducted several financing rounds. Prior to this, he was EVP Innovation at…

TBA
E-CEL® (En­gi­neered En­dothe­lial Cell) Ther­a­py and Vas­cu­lar Niche Bi­ol­o­gy
0cd4bfe005de1c4150639ce4e34c5a66_cf8c6580c5d00b26076133b4e22fb0cc_120_120
Angiocrine Bioscience
Paul Finnegan , CEO / Angiocrine Bioscience
Dr. Finnegan is Chief Executive Officer of Angiocrine Bioscience. He has more than 20 years of life science management experience in the biotechnology, pharmaceutical, and healthcare industries
Export to Excel